Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Immunol Res. 2019 Oct 28;7(12):1903–1909. doi: 10.1158/2326-6066.CIR-18-0793

Figure 2.

Figure 2.

A, Scans from a patient with fibrolamellar hepatocellular carcinoma who received sequential radiation and ipilimumab to a metastatic lesion in the left upper lobe of the lung. At 6 months after treatment, the in-field lesion (i.e., that which received SABR 50 Gy in 4 fractions) had completely resolved (top row). A large lesion that received low-dose radiation (mean dose 305 cGy) also resolved (middle row), but several other lesions in the lower lungs, outside the radiation field, did not respond (bottom row). B, Responding out-of-field lesions that that received low-dose radiation (n=16) or no low-dose radiation (n=95). Response was defined as a decrease in tumor volume of at least 50%. Fisher’s exact P=0.0091.